

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: CB2 Insights Inc. (the "Issuer").

Trading Symbol: CBII

Number of Outstanding Listed Securities: 79,997,556

Date: August 01, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On July 9, 2019 the Issuer announced that it has successfully completed Phase One of its Clinical Decision Support (CDS) tool integration including targeted user testing with its partner Premier Health Group (CSE:PHGI). Premier Health's leading Electronic Medical Records (EMR) platform, Juno,

provides the Company with access to its more than 4,600 primary care physician and healthcare practitioner users. Upon integration, users will be able to leverage the industry's only data-driven platform that guides clinicians through the evaluation process for medical cannabis treatment. After a successful completion and user feedback within this first stage, both parties anticipate full rollout will be completed in Q3.

The partnership aligns directly with CB2 Insight's mission to mainstream medical cannabis into traditional healthcare. The agreement will be the first of its kind, with primary care physicians previously lacking the resources and tools required to assess the validity of medical cannabis as a treatment option for their patients. The CDS tool provides comprehensive guidelines for physicians to input patient-specific parameters into the system which is powered by proprietary algorithms leveraging data from more than 500 clinical research papers and trials as well as the anonymized and aggregate data of more than 450,000 patient encounters that CB2 Insights has managed through its clinical arm.

"Physicians are the gatekeepers to any pharmacological treatment option for patients and enabling them to include medical cannabis into those options is a key advancement in the industry that all stakeholders should be excited about," said Prad Sekar, CEO of CB2 Insights. "The success of this project thus far is confirmation that healthcare practitioners have been awaiting the tools that will help them remove the barriers that persist in the complicated world of medical cannabis. When you are dealing with a new treatment that can be applied to a wealth of patient indications from chronic pain to anxiety to sleep disorders and so on, paired with an array of medicine with varying levels of strength and outcome, we are proud to have created a tool that has received overwhelming physician support in this first stage."

"At Premier Health, our mission is to integrate the best CDS tools directly into our Juno EMR platform that will equip physicians to make enhanced health-related decisions," said Dr. Essam Hamza, CEO of Premier Health. "Our work with CB2 Insights has been long awaited by physicians who understand the benefits of medical cannabis, however are unsure of how to incorporate it within their clinics. We are excited to be bringing this robust and medically validated tool to our Juno user base."

As part of Phase One, users were given the opportunity to test the system and provide feedback on both the applicability and user experience of the tool. The group of physicians who took part in Phase One included cannabis naïve physicians as well as those with advanced medical cannabis experience. Based on the positive feedback received from physicians, both parties agreed to immediately move into the final integration phase.

This agreement marks the first full-scale commercialization of the Company's Data Insights business unit. CB2 Insights expects to monetize this tool through subscription of data reports paid for by Cannabis Licensed Producers from the aggregate and anonymized data collected on Canadian products. These reports will provide Producers with much needed clinically-generated efficacy

data on specific products as well as the aggregate data to support research & development efforts and future commercialization. CB2 has already had successful conversations with Licensed Producers who have shown early commitment to subscribe to these reports.

As part of the agreement, CB2 will provide the development and continuous maintenance and support of the CDS tool and all related technologies. Premier Health will support the partnership by providing access to their software and will engage in education and training to its growing network of physicians and other healthcare professionals.

On July 18, 2019 the Issuer announced that it has been selected as exclusive research technology platform for the leading, and only, independent scientific body on drugs in the UK, working to provide evidence-based information on safety and efficacy within medical cannabis. A Letter of Intent has been signed between CB2 and Drug Science.

"It is not often that a drug enters the market ahead of well established, widely held consensus on the health impact related to that drug," said David Badcock, CEO, Drug Science. "Project TWENTY21 has been designed to remove the barriers that come with a lack of evidence-based data so that physicians can become more confident, the industry can become more informed and patients can have access where and when cannabinoid treatment is appropriate. We believe that Project TWENTY21 will change the landscape in the UK medical cannabis field, and this partnership with CB2 Insights advances that effort in a major way."

CB2 Insights will also join the Drug Science working group, which is led by Drug Science, patient organisations, academia and industry leaders including Licensed Producers Althea, Cannuba and Alta Flora. CB2 and the working group aims to create the UK's only independent GDPR-compliant database of patient health data focused on assessing the health-related outcomes of patients suffering from chronic pain, PTSD, multiple sclerosis, Tourette's syndrome and other indications after the integration of medical cannabis therapy into (or as a replacement for) traditional treatment regimens.

"Having built the industry's first cannabis-specific research platform and largest single patient registry with over 25 represented indications generated with insights from over 400,000 patient interactions across the US, we are thrilled to extend our expertise to the UK," said Prad Sekar, CEO, CB2 Insights. "The UK market has substantial potential for rapid advancement for medical cannabis adoption. Drug Science is the only organization bringing evidence-based understanding to the UK market, and this represents a tremendous opportunity for CB2 to expand our data pool and extract more real-world evidence. We look forward to contributing our expertise to the Drug Science working group."

In 2016, the UK was the largest exporter of legal cannabis representing roughly 70% of the world's total. But with domestic medical use legalization put

into effect in 2018, patients still find that accessing the treatment option is difficult. Physicians remain the gatekeepers to prescribing cannabis, and a lack of data and understanding of how to integrate the treatment effectively has been seen as a key barrier forcing patients to seek other non-regulated sources of medication.

Since November 2018, medical cannabis has been legal for patients in the UK although, like other jurisdictions around the world, limited data sets are available to help physicians, patients, regulatory bodies and other key stakeholders make informed decisions related to this treatment option.

On July 31, 2019 the Issuer announced that it had appointed former Johnson & Johnson executive Peter Cummins as a Director to its Board, increasing the size of its Board of Directors to seven (7) members.

"The high interest and development potential that exists between medical cannabis and traditional healthcare is enormous", said Mr. Cummins. "CB2 Insights is the bridge between these two industries through clinically-driven observational data which is key to the development of cannabis-based medicine by pharmaceutical companies across the globe. I am excited about the Company's prospects and look forward to assist and guide in the execution of their strategy to provide best-in-class medical cannabis research support to the healthcare industry."

Mr. Cummins adds a depth of experience to CB2 Insights from the traditional healthcare sector. He spent over two decades with Johnson & Johnson, including executive leadership roles overseeing research and development, product development, external innovation, regulatory affairs and hospital pharmacy across Canada, the US, Europe and other regions. Prior to Johnson & Johnson, Mr. Cummins served in Regulatory and Scientific Affairs at Procter & Gamble, and he was the Director of Pharmacy at Cambridge Memorial Hospital. He holds a BSc in Pharmacy from the University of Toronto and an MBA from Wilfred Laurier University.

"Peter has extensive experience in traditional pharmaceutical research and development. He brings a crucial understanding and network to CB2 Insights that will undoubtedly help to unlock the value of the Company's data assets moving forward," said David Danziger, Chairman of the Board, CB2 Insights.

This new appointment increases the number of board members from 6 to 7, with a majority of independent Directors with experience in corporate finance, taxation, auditing, capital markets, technology, data analytics, medical cannabis, healthcare and pharmaceuticals.

2. Provide a general overview and discussion of the activities of management.

None other than as described in 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- None other than as described in 1 above.*
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
- n/a*
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
- n/a*
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
- n/a*
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
- n/a*
8. Describe the acquisition of new customers or loss of customers.
- n/a*
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
- n/a*
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
- n/a*
11. Report on any labour disputes and resolutions of those disputes if applicable.
- n/a*

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
n/a
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
n/a
14. Provide details of any securities issued and options or warrants granted.
n/a
15. Provide details of any loans to or by Related Persons.
n/a
16. Provide details of any changes in directors, officers or committee members.
On July 31, 2019 the Issuer added a seventh director to the board, Peter Cummins. See 1 above.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 01, 2019.

Kash Qureshi

Name of Director or Senior
Officer

"signed"

Signature

COO

Official Capacity

Issuer Details Name of Issuer CB2 Insights Inc.	For Month End July	Date of Report YY/MM/D 19/08/01
Issuer Address 5045 Orbitor Drive		
City/Province/Postal Code Mississauga, ON L4W 4Y4	Issuer Fax No. ()	Issuer Telephone No. (855) 874-4999
Contact Name Catherine Beckett	Contact Position Manager Corporate Affairs	Contact Telephone No. 416-642-1807